Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Brittany Siontis (NPI 1659634822)

Field	Value
Entity Type	Individual
Organization	Brittany Siontis
Address	200 1st St Sw
City	Rochester
State	MN
ZIP	55905
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 21, 2012

Payer Source	Total Paid
Medicare	$960.6K
Medicaid	$0

Key Findings

BRITTANY SIONTIS, Medical Oncology Physician in ROCHESTER, MN, has an NPI enumerated 2012-06-21 (~14 years ago) and reports $960.6K in lifetime Medicare revenue and none (no Medicaid billing on file) for Medicaid. This tenure suggests more than a decade of Medicare participation while the practice appears effectively single‑payer in the public programs represented here.

Revenue is highly concentrated: the precomputed top 3 Medicare codes account for 80.0% of this provider's total Medicare revenue, driven by J9271 ($491.5K, 51.5%), J9144 ($184.7K, 19.4%), and J9299 ($86.4K, 9.1%). These three monoclonal antibody/immunotherapy codes dominate the billing profile and explain the majority of the $960.6K Medicare total.

The code mix indicates an infusion‑centric oncology practice focused on high-cost immune and targeted therapies: J9271 (pembrolizumab), J9144 (daratumumab), and J9299 (nivolumab) are the top revenue drivers. Traditional chemotherapy and administration codes are present but represent much smaller revenue shares (for example, 96413 $29.3K, 3.1% and 96375 $4.4K, 0.5%), pointing to an operation that prioritizes biologic/immunotherapy infusions over high-volume conventional chemo.

Competitive standing on the flagship drug J9271 is middling nationally: this provider’s J9271 activity ranks #884 of 1841 providers nationally (52th percentile; typical, unremarkable volume for this code), indicating a typical, neither-dominant nor negligible presence in pembrolizumab administration compared with peers. Given J9271 represents 51.5% of her Medicare revenue, this mid‑level rank implies dependence on a single widely used immune checkpoint inhibitor delivered at a routine volume for the specialty.

By contrast, the provider’s use of J9144 and J9299 is weaker versus national peers: J9144 ranks #498 of 615 providers (19th percentile; typical, unremarkable volume for this code) and J9299 ranks #503 of 505 providers (0th percentile; typical, unremarkable volume for this code). Those ranks show relatively low national standing for daratumumab and virtually no standing for nivolumab despite both contributing materially to revenue (19.4% and 9.1% respectively), suggesting a clinical mix that favors certain immunotherapies over others.

The payer mix is effectively single‑payer (Medicare): $960.6K in Medicare revenue versus none for Medicaid, which concentrates reimbursement risk and negotiating leverage around Medicare rates and coverage. Analysts should treat Medicaid-related access, reimbursement, and state‑level contracting as non‑factors for this provider based on the available billing record.

The presence of biosimilars and supportive care products in the profile—Q5119 (rituximab biosimilar) $31.9K (3.3%), Q5118 (bevacizumab biosimilar) $23.8K (2.5%), and J2506 (pegfilgrastim) $16.1K (1.7%)—indicates adoption of biosimilar therapy and standard supportive agents alongside primary immunotherapies. These items suggest the practice incorporates cost‑mitigation tools and standard supportive oncology care, which can affect drug mix economics and contracting strategy.

Routine E/M and infusion administration revenue is small relative to drug dollars: 99213 $3K (0.3%), 99214 $2.9K (0.3%), and G0498 $5.7K (0.6%) all contribute minor shares to the Medicare total. This pattern—large drug‑dollar dependence with modest professional/administration revenue—aligns with an outpatient infusion practice model where drug reimbursement drives the financial profile rather than office visit volume.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	12,600	$40	$491.5K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	4,860	$40	$184.7K
J9299	Injection, nivolumab, 1 mg	3,600	$20	$86.4K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	3,210	$10	$32.1K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,520	$20	$31.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	280	$100	$29.3K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	990	$20	$23.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	190	$80	$16.1K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	80	$130	$10.2K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	30	$210	$5.7K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Brittany Siontis — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	70	7,200	$40	$323.3K
J9144	13	50	3,780	$40	$163.7K
J9299	20	20	5,240	$20	$159.4K
J2506	11	20	290	$80	$34.3K
Q5118	8	20	990	$20	$33.7K
Q5119	9	30	1,380	$20	$29.5K
J9264	2	10	2,760	$10	$27.1K
J9217	42	80	80	$130	$17.1K
96413	21	230	70	$100	$11.5K
99214	7,565	10,100	70	$80	$8.1K

Showing 1–10 of 45

Nearby Providers

Other providers in the same ZIP code as Brittany Siontis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$74.3M
Mayo Collaborative Services, Inc	MN	Clinical Medical Laboratory	$6.5M	$39.2M
Mayo Clinic	MN	Clinical Medical Laboratory	$12.2M	$15.2M
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$10.9M
Mayo Foundation For Medical Education & Research	MN	Durable Medical Equipment & Medical Supplies	$9.3K	$2.8M
Vidhu Kaushik	MN	Clinical Pathology/Laboratory Medicine Physician	$59.6K	$1.9M
Roberto Leon Ferre	MN	Medical Oncology Physician	$1.3M	$0
Peter Noseworthy	MN	Cardiovascular Disease Physician	$1.1M	$0
Daniel Childs	MN	Medical Oncology Physician	$1.1M	$0
Robert Jacobson	MN	Pediatrics Physician	$975.6K	$0

Brittany Siontis — Billing Profile & Reimbursement Data

Sign up for Brittany Siontis — Billing Profile & Reimbursement Data policy alerts

Brittany Siontis — Billing Profile & Reimbursement Data

Sign up for Brittany Siontis — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References